CN1861153A - Medicinal composition used for treating pharyngitis, its prepn. method and its quality control method - Google Patents
Medicinal composition used for treating pharyngitis, its prepn. method and its quality control method Download PDFInfo
- Publication number
- CN1861153A CN1861153A CN 200610042650 CN200610042650A CN1861153A CN 1861153 A CN1861153 A CN 1861153A CN 200610042650 CN200610042650 CN 200610042650 CN 200610042650 A CN200610042650 A CN 200610042650A CN 1861153 A CN1861153 A CN 1861153A
- Authority
- CN
- China
- Prior art keywords
- water
- solution
- radix
- add
- volatile oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 201000007100 Pharyngitis Diseases 0.000 title claims abstract description 23
- 238000003908 quality control method Methods 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 title claims description 12
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims abstract description 30
- 239000000463 material Substances 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 80
- 239000000243 solution Substances 0.000 claims description 65
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 60
- 239000000341 volatile oil Substances 0.000 claims description 53
- 238000012360 testing method Methods 0.000 claims description 46
- 241000628997 Flos Species 0.000 claims description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 36
- 239000000796 flavoring agent Substances 0.000 claims description 33
- 235000019634 flavors Nutrition 0.000 claims description 33
- 239000000706 filtrate Substances 0.000 claims description 30
- 239000007788 liquid Substances 0.000 claims description 28
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 27
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 26
- 239000006228 supernatant Substances 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000013558 reference substance Substances 0.000 claims description 19
- 238000004821 distillation Methods 0.000 claims description 16
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 14
- 238000012856 packing Methods 0.000 claims description 14
- 210000000582 semen Anatomy 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 241000245240 Lonicera Species 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- 238000010992 reflux Methods 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- 239000007921 spray Substances 0.000 claims description 10
- 239000006188 syrup Substances 0.000 claims description 10
- 235000020357 syrup Nutrition 0.000 claims description 10
- 238000004809 thin layer chromatography Methods 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 239000012567 medical material Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 6
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 6
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 6
- 229940074393 chlorogenic acid Drugs 0.000 claims description 6
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 6
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 6
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 6
- ROAYSRAUMPWBQX-UHFFFAOYSA-N ethanol;sulfuric acid Chemical compound CCO.OS(O)(=O)=O ROAYSRAUMPWBQX-UHFFFAOYSA-N 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 239000012085 test solution Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 229960000583 acetic acid Drugs 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 2
- 241000238370 Sepia Species 0.000 claims description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 2
- 244000061458 Solanum melongena Species 0.000 claims description 2
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- RTEXIPZMMDUXMR-UHFFFAOYSA-N benzene;ethyl acetate Chemical compound CCOC(C)=O.C1=CC=CC=C1 RTEXIPZMMDUXMR-UHFFFAOYSA-N 0.000 claims description 2
- MDHYEMXUFSJLGV-UHFFFAOYSA-N beta-phenethyl acetate Natural products CC(=O)OCCC1=CC=CC=C1 MDHYEMXUFSJLGV-UHFFFAOYSA-N 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 claims description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 2
- OAIVIYSBZFEOIU-UHFFFAOYSA-N chloroform;propan-2-one Chemical compound CC(C)=O.ClC(Cl)Cl OAIVIYSBZFEOIU-UHFFFAOYSA-N 0.000 claims description 2
- 230000018044 dehydration Effects 0.000 claims description 2
- 238000006297 dehydration reaction Methods 0.000 claims description 2
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims description 2
- 235000011477 liquorice Nutrition 0.000 claims description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003507 refrigerant Substances 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000001117 sulphuric acid Substances 0.000 claims description 2
- 235000011149 sulphuric acid Nutrition 0.000 claims description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical group COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 2
- 235000012141 vanillin Nutrition 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 2
- LSYBEKRLBPCVES-UHFFFAOYSA-N ethyl acetate formic acid Chemical compound C(C)(=O)OCC.C(=O)O.C(=O)O LSYBEKRLBPCVES-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 16
- 206010044008 tonsillitis Diseases 0.000 abstract description 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 2
- 241000208843 Arctium Species 0.000 abstract 2
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract 2
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract 2
- 235000006751 Platycodon Nutrition 0.000 abstract 2
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 229930189914 platycodon Natural products 0.000 abstract 2
- 235000007516 Chrysanthemum Nutrition 0.000 abstract 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 201000008197 Laryngitis Diseases 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 12
- 230000036407 pain Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229920000858 Cyclodextrin Polymers 0.000 description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 206010018691 Granuloma Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 208000016150 acute pharyngitis Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical group O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 2
- 239000008517 radix Trichosanthis Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000255791 Bombyx Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- -1 Radix Scutellariae Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000010231 banlangen Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000009438 liyan Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating pharyngitis, laryngitis, laryngalgia, tonsillitis, etc is prepared from 16 Chinese-medicinal materials including honeysuckle flower, mint, arctium fruit, platycodon root, etc. Its quality control method includes the thin-layer discrimination to mint, arctium fruit, liquorice root, platycodon root and ophiopogon root, examining the relative density and pH value and measuring the contents of honeysuckle flower and chrysanthemum. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and method for making thereof and method of quality control, especially for pharmaceutical composition and the method for making and the method for quality control of treatment sore throat.
Background technology
Acute and chronic pharyngitis is common clinical, frequently-occurring disease, belongs to traditional Chinese medical science sore throat category, and the Chinese herb decoction opinion is controlled, and reasonable curative effect is arranged.Chinese patent gazette disclosed name to be called " peaceful aerosol of quick-acting throats and compound method ", publication number was 1117862 patent application on March 6th, 1996, this aerosol medicinal liquid is mainly made by Radix Scrophulariae, Flos Lonicerae, Fructus Forsythiae, Rhizoma Belamcandae, Radix Sophorae Tonkinensis, Radix Platycodonis, Oleum menthae, Borneolum Syntheticum, Borax etc., lays particular emphasis on heat-clearing and toxic substances removing.And contain Radix Ophiopogonis, Radix Glehniae, Fructus Corni (processed), Fructus Crataegi, Radix Glycyrrhizae in the present invention's prescription, and lay particular emphasis on nourishing lung and kidney, sour sweet stomach function regulating, be intended to effect a permanent cure.2005 editions " Chinese pharmacopoeia liyan jiedu granule is by making Radix Isatidis, Flos Lonicerae, Fructus Forsythiae, Herba Menthae, Fructus Arctii (parched), Fructus Crataegi (parched to brown), Radix Platycodonis, Folium Isatidis, Bombyx Batryticatus, Radix Scrophulariae, Radix Scutellariae, Radix Rehmanniae, Radix Trichosanthis, Radix Et Rhizoma Rhei, Bulbus Fritillariae Thunbergii, Radix Ophiopogonis.By comparison, the present invention attached flavour of a drug Fructus Corni, Radix Glehniae, Radix Ophiopogonis with nourishing lung and kidney, Yin-nourishing and body fluid promoting, is intended to fundamentally deal with problems on the basis of heat-clearing and toxic substances removing; And the prescription in the pharmacopeia is formed with relieving the exterior syndrome with drugs of pungent in flavor and cool in nature, and removing heat from the lung and relieving sorethroat, to bring down a fever be main, except that Fructus Arctii, Herba Menthae, used flavour of a drug such as Radix Scutellariae, Radix Trichosanthis, Radix Et Rhizoma Rhei.
Summary of the invention
The objective of the invention is to: provide a kind of treatment evident in efficacy acute and chronic bronchitis, the pharmaceutical composition of upper respiratory tract infection and method for making thereof and method of quality control.
The present invention is achieved in that according to components by weight percent and calculates, and makes this pharmaceutical composition raw materials of effective components to be: Flos Lonicerae 50-150g, Fructus Forsythiae 50-150g, Fructus Arctii 25-75g, Herba Houttuyniae 25-75g, Herba Menthae 18-53g, Flos Chrysanthemi 18-53g, Rhizoma Belamcandae 50-150g, Radix Sophorae Tonkinensis 25-75g, Radix Scrophulariae 50-150g, Radix Platycodonis 18-53g, Semen Sterculiae Lychnophorae 18-53g, Radix Ophiopogonis 50-150g, Radix Glehniae 18-53g, Fructus Corni (processed) 50-150g, Fructus Crataegi 50-150g, Radix Glycyrrhizae 10-30g.Best: Flos Lonicerae 100g, Fructus Forsythiae 100g, Fructus Arctii 50g, Herba Houttuyniae 50g, Herba Menthae 35g, Flos Chrysanthemi 35g, Rhizoma Belamcandae 100g, Radix Sophorae Tonkinensis 50g, Radix Scrophulariae 100g, Radix Platycodonis 35g, Semen Sterculiae Lychnophorae 35g, Radix Ophiopogonis 100g, Radix Glehniae 35g, Fructus Corni (processed) 100g, Fructus Crataegi 100g, Radix Glycyrrhizae 20g.
Pharmaceutical composition of the present invention can be made acceptable forms on the pharmaceutics, comprise pill, granule, tablet, syrup, mixture, oral liquid, drop pill, capsule, injection, slow releasing preparation or controlled release preparation etc., preferred oral liquid, syrup, granule, capsule, tablet, special preferred oral liquid.
Medicament composition granule agent preparation method of the present invention: Fructus Forsythiae, Herba Menthae and Herba Houttuyniae three flavors add the water distillation, and it is standby to extract volatile oil, and debris device is in addition collected, and volatile oil is made clathrate; All the other Flos Loniceraes, Fructus Arctii etc. 13 flavor decocts with water, and filters, and will extract the medicinal residues adding behind the volatile oil again, decoct with water, filter merging filtrate and above-mentioned debris, concentrating under reduced pressure, get supernatant and reclaim ethanol and be condensed into extractum, add appropriate amount of auxiliary materials, granulate, dry, with volatile oil clathrate compound mixing, packing, promptly.
Medicament composition capsule agent preparation method of the present invention: Fructus Forsythiae, Herba Menthae and Herba Houttuyniae three flavors add the water distillation, and it is standby to extract volatile oil, and debris device is in addition collected, and volatile oil is made clathrate; All the other Flos Loniceraes, Fructus Arctii etc. 13 flavor decocts with water, and filters, and will extract the medicinal residues adding behind the volatile oil again, decoct with water, filter merging filtrate and above-mentioned debris, concentrating under reduced pressure, get supernatant and reclaim ethanol and be condensed into extractum, add appropriate amount of auxiliary materials, granulate, dry, with the volatile oil clathrate compound mixing, encapsulated, promptly.
Pharmaceutical composition method for preparing tablet thereof of the present invention: Fructus Forsythiae, Herba Menthae and Herba Houttuyniae three flavors add the water distillation, and it is standby to extract volatile oil, and debris device is in addition collected, and volatile oil is made clathrate; All the other Flos Loniceraes, Fructus Arctii etc. 13 flavor decocts with water, and filters, and will extract the medicinal residues adding behind the volatile oil again, decoct with water, filter merging filtrate and above-mentioned debris, concentrating under reduced pressure is got supernatant and is reclaimed ethanol and be condensed into extractum, adds appropriate amount of auxiliary materials, granulate, drying is with volatile oil clathrate compound mixing, tabletting, packing, promptly.
Pharmaceutical composition syrup preparation method of the present invention: Fructus Forsythiae, Herba Menthae and Herba Houttuyniae three flavors add the water distillation, and it is standby to extract volatile oil, and debris device is in addition collected; All the other Flos Loniceraes, Fructus Arctii etc. 13 flavor decocts with water, and filters, and the medicinal residues that will extract again behind the volatile oil add, and decoct with water, filter, and merging filtrate and above-mentioned debris, concentrating under reduced pressure is got supernatant and is reclaimed ethanol and concentrated; Other gets sucrose and makes syrup, with above-mentioned concentrated solution mixing, boils, and puts coldly, and appropriate amount of auxiliary materials transfers to 1000ml, packing, and sterilization, promptly.
Drug composition oral liquid and preparation method thereof of the present invention: Fructus Forsythiae, Herba Menthae and Herba Houttuyniae three flavors add the water distillation, and it is standby to extract volatile oil, and debris device is in addition collected; All the other Flos Loniceraes, Fructus Arctii etc. 13 flavor decocts with water, and filters, and will extract the medicinal residues adding behind the volatile oil again, decoct with water, filter merging filtrate and above-mentioned debris, concentrating under reduced pressure is got supernatant and is reclaimed ethanol and concentrated, gets supernatant and filters, filtrate adds above-mentioned volatile oil and appropriate amount of auxiliary materials, transfer to 1000ml, filter packing, sterilization, promptly.Preferably: Fructus Forsythiae, Herba Menthae and Herba Houttuyniae three flavors add 14 times of water gaging distillations 6 hours, and it is standby to extract volatile oil, and debris device is in addition collected; All the other Flos Loniceraes, 13 flavors such as Fructus Arctii decoct with water three times, and 2 hours for the first time, 1.5 hours for the second time, amount of water is respectively 12 times and 10 times, and collecting decoction filters, medicinal residues behind medicinal residues and the extraction volatile oil merge, and add 10 times of water gagings again, decoct 1 hour, filter, merging filtrate and above-mentioned debris, relative density is 1.10～1.12 when being evaporated to 60 ℃, adding ethanol makes and contains alcohol amount and reach 70%, left standstill 24 hours, relative density is 1.04 when getting supernatant recovery ethanol and being concentrated into 20 ℃, leaves standstill 48 hours, getting supernatant filters, filtrate adds volatile oil and appropriate amount of auxiliary materials, adjusts volume to 1000ml, adjust pH to 5.0～7.0, filter, packing, sterilization, promptly.
The method of quality control of drug composition oral liquid of the present invention is as follows:
[character] this product is the sepia supernatant liquid; Gas is refrigerant, the sweet little hardship of distinguishing the flavor of.
This product 20ml is got in [discriminating] (1), and with petroleum ether (60 ~ 90 ℃) 15ml extraction 1 time, extract is concentrated into about 1ml, as need testing solution.It is an amount of that other gets the Mentholum reference substance, makes the solution that every 1ml contains 2mg with ether, in contrast product solution.Test according to the Chinese Pharmacopoeia thin layer chromatography, draw above-mentioned two kinds of each 2ul of solution, putting respectively on same silica gel G plate, is developing solvent with benzene-ethyl acetate (19: 1), launches, take out, dry, spray is with vanillin sulphuric acid-ethanol (2: 8) test solution, and 100 ℃ of heating 5min are to clear spot, in the test sample chromatograph, with the corresponding position of reference substance chromatograph on show identical aubergine speckle.
(2) get this product 15ml, add ammonia 1.5ml jolting mixing, use chloroform extraction three times, each 25ml, combined chloroform liquid, water bath method, residue add methanol 1ml makes dissolving, as need testing solution.Other gets Fructus Arctii control medicinal material 1g, adds ethanol 20ml, and reflux 1h filters, and filtrate evaporate to dryness, residue add ethanol 2ml makes dissolving, in contrast medical material solution.According to the test of Chinese Pharmacopoeia thin layer chromatography, draw each 10 μ l of above-mentioned two kinds of solution, put respectively on same above-mentioned silica gel g thin-layer plate, with chloroform-methanol (10: 1) is developing solvent, launches, and takes out, dry, spray is with 10% sulphuric acid ethanol test solution, and 105 ℃ to be heated to speckle colour developing clear.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show identical blue spot.
(3) get this product 20ml, put in the separatory funnel, use water saturation n-butanol extraction 3 times, each 15ml merges n-butyl alcohol liquid, washes with water 3 times, each 20ml, and water bath method, residue add methanol 2ml makes dissolving, as need testing solution.Extracting liquorice control medicinal material 1g in addition, the 40ml that adds diethyl ether, reflux 1h, filter, medicinal residues add methanol 30ml reflux 1h, filter, filtrate evaporate to dryness, residue add water 40ml makes dissolving, uses n-butanol extraction 3 times, each 20ml merges n-butyl alcohol liquid, washes with water 3 times, each 20ml, n-butyl alcohol liquid evaporate to dryness, residue add methanol 5ml makes dissolving, in contrast medical material solution.Test according to the Chinese Pharmacopoeia thin layer chromatography, draw above-mentioned two kinds of each 2ul of solution, put respectively on same silica gel G plate, (15: 1: 1.5: 2) be developing solvent, expansion was taken out with ethyl acetate-formic acid-glacial acetic acid-water, dry, spray is with 10% sulphuric acid ethanol test solution, and 105 ℃ to be heated to the speckle colour developing clear, puts under the uviol lamp (365nm) and inspect.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on show the speckle of same color.
(4) get this product 10ml, put in the round-bottomed flask, add hydrochloric acid 3ml, water-bath reflux 30 minutes, cool, put in the separatory funnel, extract 3 times the combined ethyl acetate extracting solution with the ethyl acetate jolting, water bath method, residue add methanol 1ml makes dissolving, as need testing solution; Other gets Radix Platycodonis control medicinal material powder 1g, adds 7% sulphuric acid alcohol-water (1: 3) mixed liquor 20ml, reflux 3 hours, put coldly, extract 2 times each 20ml with the chloroform jolting, combined chloroform liquid, add water 30ml washing, discard washing liquid, the chloroform solution anhydrous sodium sulfate dehydration, filter, filtrate evaporate to dryness, residue add methanol 1ml makes dissolving, in contrast medical material solution.According to Chinese Pharmacopoeia thin layer chromatography test, draw need testing solution 10ul, reference substance solution 5ul, put respectively in same be on the silica gel G plate of adhesive with the sodium carboxymethyl cellulose, be developing solvent with chloroform-ether (1: 1), launch, taking-up is dried.Spray is with 10% ethanol solution of sulfuric acid, and 105 ℃ to be heated to the speckle colour developing clear.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
(5) get this product 20ml, put in the round-bottomed flask, add hydrochloric acid 6ml, water-bath reflux 1 hour cools, and puts in the separatory funnel, extracts 3 times with the ethyl acetate jolting, and combined ethyl acetate extracting solution, water bath method, residue add methanol 1ml makes dissolving, as need testing solution; Other gets control medicinal material 1g Radix Ophiopogonis, adds water 10ml, decocts 30 minutes, filter, filtrate adds hydrochloric acid 2ml, and heating makes and keeps little boiling 10 minutes, cools, put in the separatory funnel, extract 3 times combined ethyl acetate extracting solution, water bath method with the ethyl acetate jolting, residue adds methanol 1ml makes dissolving, in contrast medical material solution; According to Chinese Pharmacopoeia thin layer chromatography test, draw need testing solution 10ul, reference substance solution 5ul, put respectively in same be on the silica gel G plate of adhesive with the sodium carboxymethyl cellulose, be developing solvent with chloroform-acetone (4: 1), launch, taking-up is dried.Spray is with 10% ethanol solution of sulfuric acid, and 105 ℃ to be heated to the speckle colour developing clear.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
[inspection] relative density: should be not less than 1.03.
PH value: should be 5.0～7.0.
Other: should meet " the pertinent regulations under the Chinese pharmacopoeia mixture item.
[assay] is according to the Chinese Pharmacopoeia high effective liquid chromatography for measuring.
Chromatographic condition and system suitability test: with octadecylsilane chemically bonded silica is filler; The glacial acetic acid solution of methanol-0.5% (20: 80) is a mobile phase; The detection wavelength is 327nm; Theoretical cam curve is pressed the chlorogenic acid peak and is calculated, and should be not less than 2000.
The preparation of reference substance solution: it is an amount of that precision takes by weighing the chlorogenic acid reference substance, adds methanol and make the solution that every ml contains 25ug, in contrast product solution.
The preparation of need testing solution: accurate this product 1ml that draws, put in the volumetric flask of 25ml, add 50% methanol and be diluted to scale, shake up, as need testing solution.
Algoscopy: accurate respectively reference substance solution and each 5ul of need testing solution of drawing, inject chromatograph of liquid, measure, promptly.
The every 10ml of this product contains Flos Lonicerae and Flos Chrysanthemi with chlorogenic acid (C
16H
18O
9) meter, should be not less than 3.0mg.
The traditional Chinese medical science thinks that the sore throat endogenous cause of ill mostly is the visceral dysfunction of lung, spleen, stomach, and exopathogenic factor mostly is wind heat and invades (or wind and cold strongly fragrant and heat-transformation), and pyretic toxicity follows through last heap soil or fertilizer over and around the roots, so that QI and blood is retarded by silt, venation numbness resistance and falling ill.This composition prescription is a monarch drug with Flos Lonicerae, Fructus Forsythiae, the heat clearing away of Radix Scrophulariae medicine, detoxifcation, eliminating stagnation; With Radix Ophiopogonis, Radix Glehniae, Fructus Corni nourishing lung and kidney is ministerial drug; Fructus Arctii, Flos Chrysanthemi, Radix Sophorae Tonkinensis, Rhizoma Belamcandae, Semen Sterculiae Lychnophorae resolving toxin and disinhibiting the throat eliminating stagnation, Herba Menthae, Radix Platycodonis lung qi dispersing are antipruritic, the Herba Houttuyniae heat-clearing and toxic substances removing, more than be adjuvant drug altogether; Fructus Crataegi, the sweet stomach function regulating coordinating the actions of various ingredients in a prescription of glycyrrhizic acid are messenger drug.All medicines gather heat-clearing and toxic substances removing, enriching yin and nourishing kidney, eliminating stagnation effect altogether, are used for the treatment of the diseases such as laryngopharynx swelling and pain that acute and chronic pharyngitis, neurosis of pharynx, tonsillitis and flu cause.
We have carried out following pharmacodynamics test with drug composition oral liquid of the present invention.
(1) analgesic experiment: adopt hot plate method and glacial acetic acid writhing method to test respectively.Get 70 of female (hot plate method) or male and female half and half (writhing method) mices, be divided into 7 groups at random, 10 every group.Be respectively: blank group (normal saline), positive controls, the present invention (1.045g/kg), the present invention (3.135g/kg), the present invention (5.225g/kg), the present invention (8.36g/kg), the present invention (10.45g/kg).Concrete test data is listed in table 1, table 2, table 3 and the table 4.
Table 1 the present invention is to mice analgesic activity hot plate reaction result (threshold of pain unit: second)
| Group | N (only) | Dosage (g/kg) | The preceding threshold of pain of administration (second) | The threshold of pain (second) | |||
| 15 minutes | 30 minutes | 60 minutes | 90 minutes | ||||
| The present invention of normal saline group morphine hydrochloride group | 10 10 10 10 10 10 10 | - 0.0075 1.045 3.135 5.225 8.36 10.45 | 21.3±4.42 20.4±6.27* 18.5±4.06 21.25±3.28 23.2±4.61 19.8±3.45 22.7±5.39 | 24.6±4.16 46.0±14.8* 25.0±8.69 31.25±9.75 30.4±9.27 29.0±13.61 27.8±7.94 | 24.5±2.99 43.7±15.6* 27.6±15.2 34.4±11.33* 32.4±9.82* 29.0±13.47 29.9±6.70* | 25.2±4.96 38.3±10.9* 33.1±16.7 32.38±16.9 29.6±14.92 26.2±9.73 31.6±7.66* | 25.1±6.15 23.4±13.1* 33.6±13.85 27.0±9.82 29.6±14.61 19.5±2.17 35.7±12.38 |
With normal saline group contrast * p＜0.05
Table 2 the present invention is to the percentile influence of easing pain of the mice hot plate threshold of pain
| Group | 15 minutes | 30 minutes | 60 minutes | 90 minutes |
| Physiological saline Zu morphine hydrochloride Zu 1.045g/kg of the present invention 3.135g/kg of the present invention 5.225g.kg of the present invention 8.36g/kg of the present invention 10.45g/kg of the present invention | 15.5％ 125.0％ 35.0％ 47.1％ 31.0％ 25.3％ 22.5％ | 15.0％ 114.0％ 49.2％ 61.8％ 39.7％ 46.5％ 31.7％ | 18.3％ 87.7％ 78.9％ 52.4％ 19.8％ 46.5％ 39.2％ | 17.8％ 14.7％ 81.6％ 27.1％ 27.6％ 32.3％ 57.3％ |
1 mouse writhing number of times of table 3 administration and pain incidence rate
| Group | Number of animals (only) | Dosage (g/kg) | Turn round the body number of times | The pain incidence rate |
| The present invention of the present invention of physiological saline Zu enteric coated aspirin | 10 10 10 10 10 10 10 | - 0.005 1.045 3.135 5.225 8.36 10.45 | 31.1±19.4 11.1±13.58* 28.1±16.67 27.0±10.26 22.5±11.32 27.5±20.30 22.3±18.62* | 100％ 80％ 100％ 100％ 100％ 80％ 90％ |
With normal saline group contrast * p＜0.05
3 (3 days) mouse writhing number of times of table 4 successive administration and pain incidence rate
| Group | Number of animals (only) | Dosage (g/kg) | Turn round the body number of times | The pain incidence rate |
| The present invention of the present invention of physiological saline Zu enteric coated aspirin | 10 10 10 10 10 10 10 | - 0.005 1.045 3.135 5.225 8.36 10.45 | 25.9±18.85 0.8±1.39** 11.3±13.70** 11.7±13.24** 14.2±17.5** 14.75±13.60** 3.3±5.35** | 100％ 70％ 90％ 80％ 80％ 100％ 70％ |
With normal saline group contrast * * p＜0.01
(2) antiinflammatory experiment: carried out experiments such as influence, the scorching experiment of influence, Mice Auricle caused by dimethylbenzene xylene, the swollen experiment of rat granuloma, the experiment of rabbit Oleum Terebinthinae pharyngitis respectively to the immunosuppressed mice immune organ weight to normal mouse immune organ.Concrete test data sees for details in table 5, table 6, table 7, table 8, the table 9.
Table 5 the present invention is to normal mouse immune organ weight's influence
| Group | Animal (only) | Give about dosage (g/kg) | Breast arteries and veins (mg) | Spleen (g) | Liver (g) |
| The present invention of the present invention of normal saline group | 10 10 10 10 10 10 | - 1.045 3.135 5.225 8.36 10.46 | 104.19±31.87 93.67±23.71 89.58±28.34 106.81±31.79 92.62±18.54 82.62±17.05 | 0.16±0.07 0.14±0.04 0.14±0.03 0.17±0.04 0.13±0.03 0.12±0.04 | 1.77±0.36 1.49±0.22 1.48±0.29 1.44±0.13* 1.49±0.35 1.31±0.20 |
Normal saline group contrast * p＜0.05
Table 6 the present invention is to the influence of immunosuppressed mice immune organ weight
| Group | Number of animals (only) | Give about dosage (g/kg) | Thymus (mg) | Spleen (g) | Liver (g) |
| The present invention of the present invention of physiological saline cyaniding cortisone | 10 10 10 10 10 10 10 | - 0.01ml/g 1.045 3.135 5.225 8.36 10.45 | 908.9±239.0 329.3±152.18** 373.3±154.4** 383.2±126.7** 379.4±205.3 343.3±174.5** 274.2±104.5** | 0.12±0.003 0.07±0.029** 0.12±0.030 0.11±0.030 0.09±0.020 0.08±0.026** 0.10±0.020** | 1.12±0.26 0.83±0.18** 1.13±0.28 1.04±0.19 1.00±0.18 0.83±0.17** 0.95±0.21 |
With normal saline group contrast * * p＜0.01
Table 7 the present invention is to the bullate influence of mice dimethylbenzene ear
| Group | n | Dosage (g/kg) | Swelling degree (mg) |
| Dosage group small dose group of the present invention among the present invention of the heavy dose of group of the positive group of matched group (model group) the present invention | 10 10 10 10 10 | - 0.1 5.225 3.135 1.045 | 4.71±1.81 2.16±1.81 1.18±1.10 0.81±0.36 2.13±1.41 |
Table 8 the present invention is to the bullate influence of rat granuloma
| Group | n | Dosage (g/kg) | Granuloma weight (mg) | |
| A left side | Right | |||
| Dosage group small dose group in the heavy dose of group of the positive group of matched group | 9 8 8 9 10 | - 0.05 5.225 3.315 1.045 | 65.51±3.71 56.52±2.06* 57.93±0.09* 59.09±3.21* 59.45±4.42 | 67.26±3.32 56.90±6.62* 59.39±4.25* 60.33±6.66* 64.97±8.06 |
Annotate: compare * p＜0.05 with matched group.
Table 9 the present invention tests rabbit Oleum Terebinthinae pharyngitis
| Group | Dosage (g/kg) | N | The result observes |
| Blank group model group treatment group | 3.315 | 888 | The pharyngeal chronic congestion state that is of the pharyngeal normal rabbits of rabbit, kermesinus, glossiness is not good enough, the mucus secretions increase, mucous epithelium is the prominent shape hypertrophy of nail, lamina propria is swelling in various degree, blood vessel hyperplasia.Treatment group state promptly is tending towards normal near the blank group |
(3) extracorporeal bacteria inhibitor test: adopt the quantitative dilution method of meat soup (percentage concentration) to measure; Stock solution of the present invention (2.0g/ml).Concrete test data is listed in the table 10.
Table 10 the present invention is to minimal bactericidal concentration (MBC, %) mensuration of common respiratory tract pathogenic bacterium
| Medicine | Staphylococcus aureus | Escherichia coli | Bacillus pyocyaneus | Group B streptococcus | Streptococcus pneumoniae |
| The present invention | 10.0 | 10.0 | 60.0 | 10.0 | 10.0 |
Above experimental result shows that the present composition can reduce the acetic acid twisting number of times of mice; Reduce the swollen weight of rat granuloma, alleviate pedal swelling degree and mice auricle swelling degree due to the rat Ovum Gallus domesticus album.But not only early stage the oozing out, swelling and ache of occurring of inflammation-inhibiting of the present composition is described, the granulation tissue hyperplasia in later stage can also reduce inflammation, analgesia, and can suppress common pathogen.Confirm that pharmaceutical composition of the present invention has analgesia, antiinflammatory and bacteriostasis.
The specific embodiment
Embodiments of the invention 1: Flos Lonicerae 150g, Fructus Forsythiae 50g, Radix Scrophulariae 150g, Radix Ophiopogonis 50g, Radix Glehniae 53g, Fructus Corni (processed) 50g, Fructus Arctii 75g, Flos Chrysanthemi 18g, Radix Sophorae Tonkinensis 75g, Rhizoma Belamcandae 50g, Semen Sterculiae Lychnophorae 53g, Herba Menthae 18g, Radix Platycodonis 53g, Herba Houttuyniae 25g, Fructus Crataegi 150g, Radix Glycyrrhizae 10g.
Fructus Forsythiae, Herba Menthae and Herba Houttuyniae three flavors add 14 times of water gaging distillations 6 hours, and it is standby to extract volatile oil, and debris device is in addition collected, and volatile oil was made clathrate with 6 times of amount beta-cyclodextrins in 2 hours at 50 ℃ of enclose; 13 flavors such as all the other Fructus Arctiis decoct with water three times, and 2 hours for the first time, 1.5 hours for the second time, amount of water is respectively 12 times and 10 times, and collecting decoction filters, the medicinal residues that will extract for the third time behind the volatile oil add, and add 10 times of water gagings, decoct 1 hour, filter, merging filtrate and above-mentioned debris, concentrating under reduced pressure (0.08MPa) to relative density 1.10～1.12 (60 ℃), left standstill 24 hours, get the extractum that supernatant reclaims ethanol and is concentrated into relative density 1.30 (20 ℃), 1 part of qinghuo reagent adds 2 times of amount sucrose, and 1 times of amount dextrin and ethanol are an amount of, granulate, drying, with the beta-cyclodextrin clathrate mixing of volatile oil, system 1000g, packing promptly gets granule.
Embodiments of the invention 2: Flos Lonicerae 50g, Fructus Forsythiae 150g, Radix Scrophulariae 50g, Radix Ophiopogonis 150g, Radix Glehniae 18g, Fructus Corni (processed) 150g, Fructus Arctii 25g, Flos Chrysanthemi 53g, Radix Sophorae Tonkinensis 25g, Rhizoma Belamcandae 150g, Semen Sterculiae Lychnophorae 18g, Herba Menthae 53g, Radix Platycodonis 18g, Herba Houttuyniae 75g, Fructus Crataegi 50g, Radix Glycyrrhizae 30g.
Fructus Forsythiae, Herba Menthae and Herba Houttuyniae three flavors add 14 times of water gaging distillations 6 hours, and it is standby to extract volatile oil, and debris device is in addition collected, and volatile oil was made clathrate with 6 times of amount beta-cyclodextrins in 2 hours at 50 ℃ of enclose; 13 flavors such as all the other Fructus Arctiis decoct with water three times, and 2 hours for the first time, 1.5 hours for the second time, amount of water is respectively 12 times and 10 times, and collecting decoction filters, the medicinal residues that will extract for the third time behind the volatile oil add, and add 10 times of water gagings, decoct 1 hour, filter, merging filtrate and above-mentioned debris, concentrating under reduced pressure is (0.08MPa) to relative density 1.10～1.12 (60 ℃), left standstill 24 hours, get the extractum that supernatant reclaims ethanol and is concentrated into relative density 1.30 (20 ℃), 1 part of qinghuo reagent adds 2 times of amount sucrose, 1 times of amount dextrin and ethanol are an amount of, granulate, drying is with the beta-cyclodextrin clathrate mixing of volatile oil, encapsulated, make 1000, packing promptly gets capsule.
Embodiments of the invention 3: Flos Lonicerae 125g, Fructus Forsythiae 75g, Radix Scrophulariae 125g, Radix Ophiopogonis 75g, Radix Glehniae 44g, Fructus Corni (processed) 75g, Fructus Arctii 63g, Flos Chrysanthemi 27g, Radix Sophorae Tonkinensis 63g, Rhizoma Belamcandae 75g, Semen Sterculiae Lychnophorae 44g, Herba Menthae 27g, Radix Platycodonis 44g, Herba Houttuyniae 38g, Fructus Crataegi 125g, Radix Glycyrrhizae 15g.
Fructus Forsythiae, Herba Menthae and Herba Houttuyniae three flavors add 14 times of water gaging distillations 6 hours, and it is standby to extract volatile oil, and debris device is in addition collected, and volatile oil was made clathrate with 6 times of amount beta-cyclodextrins in 2 hours at 50 ℃ of enclose; 13 flavors such as all the other Fructus Arctiis decoct with water three times, 2 hours for the first time, 1.5 hours for the second time, amount of water was respectively 12 times and 10 times, collecting decoction, filter, will extract the medicinal residues adding behind the volatile oil for the third time, add 10 times of water gagings, decocted 1 hour, filter, merging filtrate and above-mentioned debris, concentrating under reduced pressure is (0.08MPa) to relative density 1.10～1.12 (60 ℃), left standstill 24 hours, get the extractum that supernatant reclaims ethanol and is concentrated into relative density 1.30 (20 ℃), 1 part of qinghuo reagent adds 2 times of amount sucrose, 1 times of amount dextrin and ethanol are an amount of, granulate, drying is with the beta-cyclodextrin clathrate and the 1% magnesium stearate mixing of volatile oil, tabletting, make 1000, packing promptly gets tablet.
Embodiments of the invention 4: Flos Lonicerae 75g, Fructus Forsythiae 125g, Radix Scrophulariae 75g, Radix Ophiopogonis 125g, Radix Glehniae 27g, Fructus Corni (processed) 125g, Fructus Arctii 38g, Flos Chrysanthemi 44g, Radix Sophorae Tonkinensis 38g, Rhizoma Belamcandae 125g, Semen Sterculiae Lychnophorae 27g, Herba Menthae 44g, Radix Platycodonis 27g, Herba Houttuyniae 63g, Fructus Crataegi 75g, Radix Glycyrrhizae 25g.
Fructus Forsythiae, Herba Menthae and Herba Houttuyniae three flavors add 14 times of water gaging distillations 6 hours, and it is standby to extract volatile oil, and debris device is in addition collected; 13 flavors such as all the other Fructus Arctiis decoct with water three times, and 2 hours for the first time, 1.5 hours for the second time, amount of water is respectively 12 times and 10 times, and collecting decoction filters, the medicinal residues that will extract for the third time behind the volatile oil add, add 10 times of water gagings, decocted 1 hour, filter, merging filtrate and above-mentioned debris, concentrating under reduced pressure (0.08MPa) to relative density 1.10～1.12 (60 ℃), left standstill 24 hours, gets supernatant and reclaim ethanol and be concentrated into relative density 1.18 (20 ℃); Other gets sucrose 650g and decocts with water, and after the dissolving, filters, and concentrates and makes syrup, with above-mentioned concentrated solution mixing, boils, and puts coldly, adds antiseptic, above-mentioned volatile oil, tween 80, adjusts volume to 1000ml, packing, and sterilization promptly gets syrup.
Embodiments of the invention 5: Flos Lonicerae 100g, Fructus Forsythiae 100g, Fructus Arctii 50g, Herba Houttuyniae 50g, Herba Menthae 35g, Flos Chrysanthemi 35g, Rhizoma Belamcandae 100g, Radix Sophorae Tonkinensis 50g, Radix Scrophulariae 100g, Radix Platycodonis 35g, Semen Sterculiae Lychnophorae 35g, Radix Ophiopogonis 100g, Radix Glehniae 35g, Fructus Corni (processed) 100g, Fructus Crataegi 100g, Radix Glycyrrhizae 20g.
Fructus Forsythiae, Herba Menthae and Herba Houttuyniae add the water distillation, and it is standby to extract volatile oil, and debris device is in addition collected; All the other Flos Loniceraes, Fructus Arctii, Rhizoma Belamcandae, Radix Sophorae Tonkinensis, Radix Scrophulariae, Radix Platycodonis, Semen Sterculiae Lychnophorae, Radix Ophiopogonis, Radix Glehniae, Fructus Corni (processed), Fructus Crataegi etc. decoct with water, and filter, and the medicinal residues behind the extraction volatile oil are added, decoct with water, filter merging filtrate and above-mentioned debris, concentrating under reduced pressure is got supernatant and is reclaimed ethanol and concentrated, gets supernatant and filters, filtrate adds above-mentioned volatile oil and appropriate amount of auxiliary materials, transfer to 1000ml, filter packing, sterilization, promptly.
Embodiments of the invention 6: Flos Lonicerae 100g, Fructus Forsythiae 100g, Fructus Arctii 50g, Herba Houttuyniae 50g, Herba Menthae 35g, Flos Chrysanthemi 35g, Rhizoma Belamcandae 100g, Radix Sophorae Tonkinensis 50g, Radix Scrophulariae 100g, Radix Platycodonis 35g, Semen Sterculiae Lychnophorae 35g, Radix Ophiopogonis 100g, Radix Glehniae 35g, Fructus Corni (processed) 100g, Fructus Crataegi 100g, Radix Glycyrrhizae 20g.
Fructus Forsythiae, Herba Menthae and Herba Houttuyniae add 14 times of water gaging distillations 6 hours, and it is standby to extract volatile oil, and debris device is in addition collected; All the other Flos Loniceraes, Fructus Arctii, Rhizoma Belamcandae, Radix Sophorae Tonkinensis, Radix Scrophulariae, Radix Platycodonis, Semen Sterculiae Lychnophorae, Radix Ophiopogonis, Radix Glehniae, Fructus Corni (processed), Fructus Crataegis etc. decoct with water three times, 2 hours for the first time, 1.5 hours for the second time, amount of water was respectively 12 times and 10 times, collecting decoction, filter, the medicinal residues behind medicinal residues and the extraction volatile oil merge, and add 10 times of water gagings again, decocted 1 hour, filter, merging filtrate and above-mentioned debris, relative density is 1.10～1.12 when being evaporated to 60 ℃, adding ethanol makes and contains alcohol amount and reach 70%, left standstill 24 hours, relative density is 1.04 when getting supernatant recovery ethanol and being concentrated into 20 ℃, leaves standstill 48 hours, getting supernatant filters, filtrate adds volatile oil and appropriate amount of auxiliary materials, adjusts volume to 1000ml, adjust pH to 5.0～7.0, filter, packing, sterilization, promptly.Oral, every 10ml, one time 1,2～3 times on the one.
Claims (10)
1, a kind of pharmaceutical composition that is used for the treatment of sore throat, it is characterized in that calculating, make this pharmaceutical composition raw materials of effective components and be according to components by weight percent: Flos Lonicerae 50-150g, Fructus Forsythiae 50-150g, Fructus Arctii 25-75g, Herba Houttuyniae 25-75g, Herba Menthae 18-53g, Flos Chrysanthemi 18-53g, Rhizoma Belamcandae 50-150g, Radix Sophorae Tonkinensis 25-75g, Radix Scrophulariae 50-150g, Radix Platycodonis 18-53g, Semen Sterculiae Lychnophorae 18-53g, Radix Ophiopogonis 50-150g, Radix Glehniae 18-53g, Fructus Corni (processed) 50-150g, Fructus Crataegi 50-150g, Radix Glycyrrhizae 10-30g.
2, the pharmaceutical composition of treatment sore throat as claimed in claim 1, it is characterized in that calculating, make this pharmaceutical composition raw materials of effective components and be according to components by weight percent: Flos Lonicerae 100g, Fructus Forsythiae 100g, Fructus Arctii 50g, Herba Houttuyniae 50g, Herba Menthae 35g, Flos Chrysanthemi 35g, Rhizoma Belamcandae 100g, Radix Sophorae Tonkinensis 50g, Radix Scrophulariae 100g, Radix Platycodonis 35g, Semen Sterculiae Lychnophorae 35g, Radix Ophiopogonis 100g, Radix Glehniae 35g, Fructus Corni (processed) 100g, Fructus Crataegi 100g, Radix Glycyrrhizae 20g.
3, the pharmaceutical composition of treatment sore throat as claimed in claim 1 or 2 is characterized in that: described pharmaceutical composition can be made acceptable forms on the pharmaceuticss such as pill, granule, tablet, syrup, mixture, oral liquid, drop pill, capsule, injection, slow releasing preparation or controlled release preparation.
4, the pharmaceutical composition of treatment sore throat as claimed in claim 3 is characterized in that the dosage form that described pharmaceutical composition is made is: oral liquid, syrup, granule, capsule, tablet.
5, the pharmaceutical composition of treatment sore throat as claimed in claim 4 is characterized in that the dosage form that described pharmaceutical composition is made is an oral liquid.
6, the preparation of drug combination method of treatment sore throat as claimed in claim 4 is characterized in that: Fructus Forsythiae, Herba Menthae and Herba Houttuyniae three flavors add the water distillation, and it is standby to extract volatile oil, and debris device is in addition collected, and volatile oil is made clathrate; All the other Flos Loniceraes, Fructus Arctii etc. 13 flavor decocts with water, and filters, and will extract the medicinal residues adding behind the volatile oil again, decoct with water, filter merging filtrate and above-mentioned debris, concentrating under reduced pressure, get supernatant and reclaim ethanol and be condensed into extractum, add appropriate amount of auxiliary materials, granulate, dry, with the volatile oil clathrate compound mixing, encapsulated, promptly get capsule.
7, the preparation of drug combination method of treatment sore throat as claimed in claim 4 is characterized in that: Fructus Forsythiae, Herba Menthae and Herba Houttuyniae three flavors add the water distillation, and it is standby to extract volatile oil, and debris device is in addition collected; All the other Flos Loniceraes, Fructus Arctii etc. 13 flavor decocts with water, and filters, and the medicinal residues that will extract again behind the volatile oil add, and decoct with water, filter, and merging filtrate and above-mentioned debris, concentrating under reduced pressure is got supernatant and is reclaimed ethanol and concentrated; Other gets sucrose and makes syrup, with above-mentioned concentrated solution mixing, boils, and puts coldly, and appropriate amount of auxiliary materials transfers to 1000ml, packing, and sterilization promptly gets syrup.
8, the preparation of drug combination method of treatment sore throat as claimed in claim 4 is characterized in that: Fructus Forsythiae, Herba Menthae and Herba Houttuyniae three flavors add the water distillation, and it is standby to extract volatile oil, and debris device is in addition collected; All the other Flos Loniceraes, Fructus Arctii etc. 13 flavor decocts with water, and filters, and will extract the medicinal residues adding behind the volatile oil again, decoct with water, filter merging filtrate and above-mentioned debris, concentrating under reduced pressure is got supernatant and is reclaimed ethanol and concentrated, gets supernatant and filters, filtrate adds above-mentioned volatile oil and appropriate amount of auxiliary materials, transfer to 1000ml, filter packing, sterilization promptly gets oral liquid.
9, the preparation of drug combination method of treatment sore throat as claimed in claim 8 is characterized in that: Fructus Forsythiae, Herba Menthae and Herba Houttuyniae three flavors add 14 times of water gaging distillations 6 hours, and it is standby to extract volatile oil, and debris device is in addition collected; All the other Flos Loniceraes, 13 flavors such as Fructus Arctii decoct with water three times, 2 hours for the first time, 1.5 hours for the second time, amount of water was respectively 12 times and 10 times, collecting decoction, filter, the medicinal residues behind medicinal residues and the extraction volatile oil merge, and add 10 times of water gagings again, decocted 1 hour, filter, merging filtrate and above-mentioned debris, relative density is 1.10～1.12 when being evaporated to 60 ℃, adding ethanol makes and contains alcohol amount and reach 70%, left standstill 24 hours, relative density is 1.04 when getting supernatant recovery ethanol and being concentrated into 20 ℃, leaves standstill 48 hours, getting supernatant filters, filtrate adds volatile oil and appropriate amount of auxiliary materials, adjusts volume to 1000ml, adjust pH to 5.0～7.0, filter, packing, sterilization promptly gets oral liquid.
10, the method for quality control of the oral liquid of treatment sore throat as claimed in claim 5 is characterized in that this method is the combination of following one or several method:
(1) the present invention is the sepia supernatant liquid, and gas is refrigerant, the sweet little hardship of distinguishing the flavor of;
(2) thin layer of Herba Menthae is differentiated: get 20ml of the present invention, with 60 ~ 90 ℃ petroleum ether 15ml extractions 1 time, extract is concentrated into about 1ml, as need testing solution; It is an amount of that other gets the Mentholum reference substance, makes the solution that every 1ml contains 2mg with ether, in contrast product solution; Test according to the Chinese Pharmacopoeia thin layer chromatography, draw above-mentioned two kinds of each 2ul of solution, putting respectively on same silica gel G plate, is that benzene-ethyl acetate of 19: 1 is developing solvent with proportioning, launches, take out, dry, spray is vanillin sulphuric acid-ethanol test solution of 2: 8 with proportioning, and 100 ℃ of heating 5min are to clear spot, in the test sample chromatograph, with the corresponding position of reference substance chromatograph on show identical aubergine speckle;
(3) thin layer of Fructus Arctii is differentiated: get 15ml of the present invention, add ammonia 1.5ml jolting mixing, use chloroform extraction three times, and each 25ml, combined chloroform liquid, water bath method, residue add methanol 1ml makes dissolving, as need testing solution; Other gets Fructus Arctii control medicinal material 1g, adds ethanol 20ml, and reflux 1h filters, and filtrate evaporate to dryness, residue add ethanol 2ml makes dissolving, in contrast medical material solution; According to the test of Chinese Pharmacopoeia thin layer chromatography, draw each 10 μ l of above-mentioned two kinds of solution, put respectively on same above-mentioned silica gel g thin-layer plate, with proportioning is that 10: 1 chloroform-methanol is developing solvent, launches, and takes out, dry, spray is with 10% sulphuric acid ethanol test solution, and 105 ℃ to be heated to speckle colour developing clear; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show identical blue spot;
(4) thin layer of Radix Glycyrrhizae is differentiated: get 20ml of the present invention, put in the separatory funnel, use water saturation n-butanol extraction 3 times, each 15ml merges n-butyl alcohol liquid, washes with water 3 times, each 20ml, and water bath method, residue add methanol 2ml makes dissolving, as need testing solution; Extracting liquorice control medicinal material 1g in addition, the 40ml that adds diethyl ether, reflux 1h, filter, medicinal residues add methanol 30ml reflux 1h, filter, filtrate evaporate to dryness, residue add water 40ml makes dissolving, uses n-butanol extraction 3 times, each 20ml merges n-butyl alcohol liquid, washes with water 3 times, each 20ml, n-butyl alcohol liquid evaporate to dryness, residue add methanol 5ml makes dissolving, in contrast medical material solution; Test according to the Chinese Pharmacopoeia thin layer chromatography, draw above-mentioned two kinds of each 2ul of solution, put respectively on same silica gel G plate, with proportioning is 15: 1: 1.5: ethyl acetate-formic acid of 2-glacial acetic acid-water is developing solvent, launches, and takes out, dry, spray is with 10% sulphuric acid ethanol test solution, and 105 ℃ to be heated to the speckle colour developing clear, puts under the 365nm uviol lamp and inspect; In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on show the speckle of same color;
(5) thin layer of Radix Platycodonis is differentiated: get 10ml of the present invention, put in the round-bottomed flask, add hydrochloric acid 3ml, water-bath reflux 30 minutes, cool, put in the separatory funnel, extract 3 times the combined ethyl acetate extracting solution with the ethyl acetate jolting, water bath method, residue add methanol 1ml makes dissolving, as need testing solution; Other gets Radix Platycodonis control medicinal material powder 1g, adds 7% proportioning and be 1: 3 sulphuric acid alcohol-water mixed liquor 20ml, reflux 3 hours, put coldly, extract 2 times each 20ml with the chloroform jolting, combined chloroform liquid, add water 30ml washing, discard washing liquid, the chloroform solution anhydrous sodium sulfate dehydration, filter, filtrate evaporate to dryness, residue add methanol 1ml makes dissolving, in contrast medical material solution; According to Chinese Pharmacopoeia thin layer chromatography test, draw need testing solution 10ul, reference substance solution 5ul, put respectively in same be on the silica gel G plate of adhesive with the sodium carboxymethyl cellulose, be that chloroform-ether of 1: 1 is developing solvent with proportioning, launch, take out, dry; Spray is with 10% ethanol solution of sulfuric acid, and 105 ℃ to be heated to the speckle colour developing clear; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
(6) thin layer of Radix Ophiopogonis is differentiated: get 20ml of the present invention, put in the round-bottomed flask, add hydrochloric acid 6ml, water-bath reflux 1 hour, cool, put in the separatory funnel, extract 3 times the combined ethyl acetate extracting solution with the ethyl acetate jolting, water bath method, residue add methanol 1ml makes dissolving, as need testing solution; Other gets control medicinal material 1g Radix Ophiopogonis, adds water 10ml, decocts 30 minutes, filter, filtrate adds hydrochloric acid 2ml, and heating makes and keeps little boiling 10 minutes, cools, put in the separatory funnel, extract 3 times combined ethyl acetate extracting solution, water bath method with the ethyl acetate jolting, residue adds methanol 1ml makes dissolving, in contrast medical material solution; According to Chinese Pharmacopoeia thin layer chromatography test, draw need testing solution 10ul, reference substance solution 5ul, put respectively in same be on the silica gel G plate of adhesive with the sodium carboxymethyl cellulose, be that chloroform-acetone of 4: 1 is developing solvent with proportioning, launch, take out, dry; Spray is with 10% ethanol solution of sulfuric acid, and 105 ℃ to be heated to the speckle colour developing clear; In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color;
(7) inspection of relative density: should be not less than 1.03;
(8) inspection of pH value: should be 5.0～7.0;
(9) assay of Flos Lonicerae and Flos Chrysanthemi: with octadecylsilane chemically bonded silica is filler; Proportioning is that the glacial acetic acid solution of 20: 80 methanol-0.5% is a mobile phase; The detection wavelength is 327nm; Theoretical cam curve is pressed the chlorogenic acid peak and is calculated, and should be not less than 2000; Accurate draw 1ml of the present invention, put in the volumetric flask of 25ml, add 50% methanol and be diluted to scale, shake up, as need testing solution; It is an amount of that precision takes by weighing the chlorogenic acid reference substance, adds methanol and make the solution that every ml contains 25ug, in contrast product solution; Accurate respectively reference substance solution and each 5ul of need testing solution of drawing, according to the Chinese Pharmacopoeia high effective liquid chromatography for measuring, the every 10ml of the present invention contains Flos Lonicerae and Flos Chrysanthemi is C with the molecular formula
16H
18O
9The chlorogenic acid meter, should be not less than 3.0mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100426508A CN100376274C (en) | 2006-04-10 | 2006-04-10 | Medicinal composition used for treating pharyngitis, its prepn. method and its quality control method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100426508A CN100376274C (en) | 2006-04-10 | 2006-04-10 | Medicinal composition used for treating pharyngitis, its prepn. method and its quality control method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1861153A true CN1861153A (en) | 2006-11-15 |
| CN100376274C CN100376274C (en) | 2008-03-26 |
Family
ID=37388739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100426508A Active CN100376274C (en) | 2006-04-10 | 2006-04-10 | Medicinal composition used for treating pharyngitis, its prepn. method and its quality control method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100376274C (en) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101979060A (en) * | 2010-11-05 | 2011-02-23 | 张沁 | Chinese medicament for treating pharyngitis |
| CN102139050A (en) * | 2011-03-13 | 2011-08-03 | 李巧玲 | Chinese medicinal formula for treating dry cough |
| CN102366438A (en) * | 2011-10-25 | 2012-03-07 | 西安交通大学 | Externally-applied Chinese medicine for eliminating swelling and preparation method thereof |
| CN102645509A (en) * | 2012-04-24 | 2012-08-22 | 西藏奇正藏药股份有限公司 | Method for detecting white vein preparation |
| CN103041146A (en) * | 2012-12-21 | 2013-04-17 | 孙红梅 | Traditional Chinese medicine composition for treating tracheitis |
| CN103656182A (en) * | 2013-12-19 | 2014-03-26 | 青岛中科菲力工程技术研发有限公司 | Traditional Chinese medicine capsule for treating tonsillitis and preparation method of capsule |
| CN103705725A (en) * | 2013-12-30 | 2014-04-09 | 广西梧州制药（集团）股份有限公司 | Throat-clearing anti-inflammatory traditional Chinese medicine composite and preparation method thereof |
| CN103948790A (en) * | 2014-05-14 | 2014-07-30 | 山东新希望六和集团有限公司 | Traditional Chinese medicinal composition for treating sphagitis of pigs and preparation method of traditional Chinese medicinal composition |
| CN104258189A (en) * | 2014-10-11 | 2015-01-07 | 侨健新能源科技（苏州）有限公司 | Traditional Chinese medicine preparation for treating chronic laryngitis |
| CN104587086A (en) * | 2014-12-25 | 2015-05-06 | 韦邦力 | Traditional Chinese medicine for treating sore throat |
| CN104721570A (en) * | 2015-04-14 | 2015-06-24 | 王付娥 | Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method thereof |
| CN105495207A (en) * | 2015-12-10 | 2016-04-20 | 覃瑞权 | Beverage capable of preventing and treating chronic pharyngitis and preparation method thereof |
| CN105521356A (en) * | 2014-11-26 | 2016-04-27 | 仲启昌 | Traditional Chinese medicine for treating pharyngitis |
| CN105796778A (en) * | 2016-05-04 | 2016-07-27 | 包莉丽 | Medicine for treating throat obstruction pharyngitis |
| CN105983049A (en) * | 2015-01-29 | 2016-10-05 | 赵士花 | Yanshu Qibao drink |
| CN108514588A (en) * | 2018-06-26 | 2018-09-11 | 桐城市泰安中药材种植专业合作社 | A kind of Chinese medicine and preparation method thereof for treating atrophic laryngitis |
| CN111888413A (en) * | 2020-09-18 | 2020-11-06 | 天津中医药大学 | Pharmaceutical composition for autumn respiratory diseases |
| CN112034062A (en) * | 2020-09-01 | 2020-12-04 | 江西济民可信药业有限公司 | Detection method of particles for clearing lung and expelling toxin |
| CN115970101A (en) * | 2022-12-30 | 2023-04-18 | 米乐医疗科技有限公司 | Handheld medical ultrasonic atomizer and using method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1133455C (en) * | 2001-11-01 | 2004-01-07 | 赵健忠 | Pharyngitis treating Chinese medicine plaster |
| CN1709434A (en) * | 2005-07-05 | 2005-12-21 | 陈周 | Chinese medicine formulation for treating sphagitis |
-
2006
- 2006-04-10 CN CNB2006100426508A patent/CN100376274C/en active Active
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101979060A (en) * | 2010-11-05 | 2011-02-23 | 张沁 | Chinese medicament for treating pharyngitis |
| CN101979060B (en) * | 2010-11-05 | 2011-11-23 | 张沁 | Chinese medicament for treating pharyngitis |
| CN102139050A (en) * | 2011-03-13 | 2011-08-03 | 李巧玲 | Chinese medicinal formula for treating dry cough |
| CN102139050B (en) * | 2011-03-13 | 2012-07-25 | 李巧玲 | Chinese medicinal formula for treating dry cough |
| CN102366438A (en) * | 2011-10-25 | 2012-03-07 | 西安交通大学 | Externally-applied Chinese medicine for eliminating swelling and preparation method thereof |
| CN102645509B (en) * | 2012-04-24 | 2014-12-24 | 西藏奇正藏药股份有限公司 | Method for detecting white vein preparation |
| CN102645509A (en) * | 2012-04-24 | 2012-08-22 | 西藏奇正藏药股份有限公司 | Method for detecting white vein preparation |
| CN103041146A (en) * | 2012-12-21 | 2013-04-17 | 孙红梅 | Traditional Chinese medicine composition for treating tracheitis |
| CN103656182A (en) * | 2013-12-19 | 2014-03-26 | 青岛中科菲力工程技术研发有限公司 | Traditional Chinese medicine capsule for treating tonsillitis and preparation method of capsule |
| CN103705725A (en) * | 2013-12-30 | 2014-04-09 | 广西梧州制药（集团）股份有限公司 | Throat-clearing anti-inflammatory traditional Chinese medicine composite and preparation method thereof |
| CN103948790A (en) * | 2014-05-14 | 2014-07-30 | 山东新希望六和集团有限公司 | Traditional Chinese medicinal composition for treating sphagitis of pigs and preparation method of traditional Chinese medicinal composition |
| CN104258189A (en) * | 2014-10-11 | 2015-01-07 | 侨健新能源科技（苏州）有限公司 | Traditional Chinese medicine preparation for treating chronic laryngitis |
| CN105521356A (en) * | 2014-11-26 | 2016-04-27 | 仲启昌 | Traditional Chinese medicine for treating pharyngitis |
| CN104587086A (en) * | 2014-12-25 | 2015-05-06 | 韦邦力 | Traditional Chinese medicine for treating sore throat |
| CN105983049A (en) * | 2015-01-29 | 2016-10-05 | 赵士花 | Yanshu Qibao drink |
| CN104721570A (en) * | 2015-04-14 | 2015-06-24 | 王付娥 | Traditional Chinese medicine composition for treating chronic pharyngitis and preparation method thereof |
| CN105495207A (en) * | 2015-12-10 | 2016-04-20 | 覃瑞权 | Beverage capable of preventing and treating chronic pharyngitis and preparation method thereof |
| CN105796778A (en) * | 2016-05-04 | 2016-07-27 | 包莉丽 | Medicine for treating throat obstruction pharyngitis |
| CN108514588A (en) * | 2018-06-26 | 2018-09-11 | 桐城市泰安中药材种植专业合作社 | A kind of Chinese medicine and preparation method thereof for treating atrophic laryngitis |
| CN112034062A (en) * | 2020-09-01 | 2020-12-04 | 江西济民可信药业有限公司 | Detection method of particles for clearing lung and expelling toxin |
| CN111888413A (en) * | 2020-09-18 | 2020-11-06 | 天津中医药大学 | Pharmaceutical composition for autumn respiratory diseases |
| CN115970101A (en) * | 2022-12-30 | 2023-04-18 | 米乐医疗科技有限公司 | Handheld medical ultrasonic atomizer and using method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100376274C (en) | 2008-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100376274C (en) | Medicinal composition used for treating pharyngitis, its prepn. method and its quality control method | |
| CN1733105B (en) | Detection method of Golden Preparation for treating gynecological disease | |
| CN1899505A (en) | Medicine composition for clearing heat and purging-fire | |
| CN103768308B (en) | A kind of pharmaceutical composition that is used for the treatment of the infection of the upper respiratory tract and preparation method thereof | |
| CN102100720B (en) | Ainsliaea fragrans champ caffeoylquinic acid extracts and preparation and application thereof | |
| CN101049424A (en) | Medication for treating infection in respiratory system | |
| CN100367994C (en) | Medicinal preparation for treating deaf and preparing method | |
| CN100444889C (en) | Chinese medicinal composition for treating mastopathy | |
| CN101185707B (en) | Antiphlogistic antiviral medicinal composition, and its preparation method and application | |
| CN1939414B (en) | Medicinal composition with antibacterial and anti-inflammation functions | |
| CN1803179B (en) | Traditional Chinese medicine composition and its preparation method and quality control method | |
| CN1233378C (en) | Chinese medicine composition for treating oral cavity and throat diseases and its preparing method | |
| CN100386093C (en) | Medicine composition for treating cold and upper respiratory tract infection, preparation method and purpose thereof | |
| CN1891285A (en) | Chinese medicine composition, and its preparing method and quality control method | |
| CN101274034B (en) | Traditional Chinese medicine composition for relieving exterior syndrome, clearing heat and detoxicating | |
| CN106389717A (en) | Piglet drug-resistant colibacillosis treating traditional Chinese medicine composition | |
| CN101670088B (en) | Traditional Chinese medicine composite for treating acute/chronic bronchitis | |
| CN1323682C (en) | Chinese medicine preparation of infectious external contraction high fever and production thereof | |
| CN1803178A (en) | Traditional Chinese medicine composition and its preparation method and quality control method | |
| CN1887328A (en) | Chinese medicine composition and its prepn process and quality control method | |
| CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
| CN1278709C (en) | Medicine for treating cold and its preparing process | |
| CN100446797C (en) | Dripping pills of 'Da Yuan Yin' and preparation method thereof | |
| CN1285372C (en) | Chinese medicine oral preparation for treating gynecologic inflammation and its preparation method | |
| CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG DANHONG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: PANG LAIXIANG Effective date: 20140515 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 710054 XI AN, SHAANXI PROVINCE TO: 274000 HEZE, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140515 Address after: 274000 No. 369 Zhonghua West Road, Heze, Shandong Patentee after: SHANDONG DANHONG PHARMACEUTICAL CO., LTD. Address before: 710054 No. 269 Youyi East Road, Shaanxi, Xi'an Patentee before: Pang Laixiang |